ASH 2023 - CLL

Final data from the phase 3 MURANO trial demonstrated a significantly prolonged time to second progression-free survival event in the venetoclax/rituximab arm, with high response rates achieved even by patients who subsequently received retreatment or crossed over to venetoclax-based regimens or BTKi therapy. Read More ›

Biomarker subgroup analysis results indicate that zanubrutinib treatment was associated with superior PFS in all biomarker subgroups analyzed compared to bendamustine/rituximab in treatment-naïve patients with CLL/SLL without del(17p). Read More ›

Results of the phase 1/2 BRUIN study indicate that fixed-duration pirtobrutinib combined with venetoclax ± rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia. Read More ›

Results of a phase 2 study suggests that the highly selective Bruton tyrosine kinase inhibitor TL-895 therapy led to rapid bone marrow clearance of leukemic cells to induce deeper and more durable responses, with a favorable adverse event profile in patients with treatment-naïve and relapsed/refractory CLL/SLL. Read More ›

Extended follow-up results of the ELEVATE-TN trial (median follow-up of 74.5 months) confirmed sustained efficacy and safety of acalabrutinib/obinutuzumab and acalabrutinib monotherapy compared to obinutuzumab/chlorambucil in patients with treatment-naïve CLL, including in patients with high-risk genetic features. Read More ›

Results of the UK FLAIR Study indicate that MRD-guided treatment duration of Ibrutinib+ venetoclax significantly improved survival outcomes compared to FCR in untreated chronic lymphocytic leukemia. Read More ›

Longer follow-up data of the GLOW study indicate that fixed-duration ibrutinib + venetoclax shows sustained PFS superiority versus chemoimmunotherapy in patients with previously untreated CLL. Read More ›

Updated results of the CAPTIVATE study show promising efficacy with ibrutinib-based retreatment in patients progressing on a first-line, fixed duration ibrutinib + venetoclax regimen. Read More ›

Longer follow-up data of the TRANSCEND CLL 004 trial indicated that lisocabtagene maraleucel continued to demonstrate durable CR/CRi and high uMRD rates in patients with heavily pretreated, high-risk R/R CLL/SLL; no new safety signals emerged. Read More ›